Human-derived Treg and MSC combination therapy may augment immunosuppressive potency in vitro, but did not improve blood brain barrier integrity in an experimental rat traumatic brain injury model

Autor: Naama E. Toledano Furman, Cecilia Martin, Karthik S. Prabhakara, Henry W. Caplan, Soheil Zorofchian, Charles S. Cox, Scott D. Olson, Hasen Xue
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Central Nervous System
Male
Critical Care and Emergency Medicine
Traumatic Brain Injury
Physiology
Cancer Treatment
Nervous System
T-Lymphocytes
Regulatory
Rats
Sprague-Dawley
Immune Physiology
Cellular types
Brain Injuries
Traumatic
Medicine
Immune Response
Trauma Medicine
Multidisciplinary
Immune cells
Regulatory T cells
Body Fluids
medicine.anatomical_structure
Blood
Oncology
Blood-Brain Barrier
White blood cells
medicine.symptom
Anatomy
Traumatic Injury
Research Article
Cell biology
Blood cells
Combination therapy
Traumatic brain injury
Science
Immunology
T cells
Inflammation
Cytokine Therapy
Blood–brain barrier
Mesenchymal Stem Cell Transplantation
Immune system
In vivo
Immune Tolerance
Animals
Humans
Neuroinflammation
Medicine and health sciences
Biology and life sciences
business.industry
Mesenchymal stem cell
Mesenchymal Stem Cells
medicine.disease
Rats
Disease Models
Animal
Animal cells
Cancer research
business
Neurotrauma
Spleen
Zdroj: PLoS ONE
PLoS ONE, Vol 16, Iss 5, p e0251601 (2021)
ISSN: 1932-6203
Popis: Traumatic brain injury (TBI) causes both physical disruption of the blood brain barrier (BBB) and altered immune responses that can lead to significant secondary brain injury and chronic inflammation within the central nervous system (CNS). Cell therapies, including mesenchymal stromal cells (MSC), have been shown to restore BBB integrity and augment endogenous splenic regulatory T cells (Treg), a subset of CD4+ T cells that function to regulate immune responses and prevent autoimmunity. We have recently shown that infusion of human cord blood-derived Treg decreased neuroinflammation after TBI in vivo and in vitro. However, while both cells have demonstrated anti-inflammatory and regenerative potential, they likely utilize differing, although potentially overlapping, mechanisms. Furthermore, studies investigating these two cell types together, as a combination therapy, are lacking. In this study, we compared the ability of Treg+MSC combination therapy, as well as MSC and Treg monotherapies, to improve BBB permeability in vivo and suppress inflammation in vitro. While Treg+MSC combination did not significantly augment potency in vivo, our in vitro data demonstrates that combination therapy may augment therapeutic potency and immunosuppressive potential compared to Treg or MSC monotherapy.
Databáze: OpenAIRE
Externí odkaz: